Pre-Made Simlukafusp biosimilar, Whole mAb Fusion, Anti-FAP Antibody: Anti-FAPA/SIMP/DPPIV/FAPalpha therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Simlukafusp benchmark antibody ( Whole mAb Fusion, anti-FAP therapeutic antibody, Anti-FAPA/SIMP/DPPIV/FAPalpha Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-521
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Simlukafusp biosimilar, Whole mAb Fusion, Anti-FAP Antibody: Anti-FAPA/SIMP/DPPIV/FAPalpha therapeutic antibody |
---|---|
INN Name | Simlukafusp |
Target | FAP |
Format | Whole mAb Fusion |
Derivation | NA |
Species Reactivity | Human |
CH1 Isotype | IgG1 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2019 |
Year Recommended | 2020 |
Companies | Roche |
Conditions Approved | NA |
Conditions Active | Malignant melanoma,Renal cell carcinoma |
Conditions Discontinued | Solid tumours |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | FAP |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide